In 2012, Oman Heart Association (OHA) published its own guidelines for the management of patients with unstable angina/ non-ST-elevation myocardial infarction, the aim was not to be comprehensive but rather simplified and practical in order to reduce the gap between the long comprehensive guidelines and our actual practice. However, we still feel that the busy registrars and residents need simpler and direct clinical pathways or protocol to be used in the emergency departments, coronary care units and in the wards. Clinical pathways are now one of the main tools used to manage the quality in healthcare concerning the standardization of care processes. It has been shown that their implementation reduces the variability in clinical practice and improves outcomes in acute care.
Introduction
Oman Heart Association has recently published the 2012
Simplified Guidelines for the Management of Patients with Unstable Angina/Non-ST Elevation Myocardial Infarction. 1 The recommendations are similar to published international guidelines, [2] [3] [4] [5] [6] [7] [8] [9] but suited for local physicians in a simplified manner. Here we publish the clinical pathways which are exclusively based on these guidelines. The aim of these clinical pathways is to provide the busy physicians in Oman with even more simple and direct approach towards implementing these guidelines into clinical practice. The emphasis is on the balance of patient's risk between ischemia and bleeding and on the optimum usage of the available medications and facilities. An attempt was made to best include all the medications available in the different health organizations all over the country to really represent a national reference. Dose: 60 U/kg IV bolus (not to exceed 4000 U), followed by IV infusion of 12 U/kg/h (not to exceed 1000 U/h) to achieve goal aPTT 1.5 to 2.0 times control (approximately 50 to 70 s); check aPTT in 6 hrs and adjust heparin as indicated. Duration: For 48 hours.
I. Risk Stratification

A. Ischemic Risk: Indicators of Early Significant Risk in
D. Anti-Remodeling Therapy
Drug
Initial Dose Target Dose 
ACE-inhibitors
E. Antilipid Agents
Statins, in the absence of contraindications, should be given to all NSTE ACS patients regardless of baseline LDL-Cholesterol and diet modification. Therapy should be initiated or intensified to achieve an LDL-C <2.6 mmol/L or <100 mg/dL. Further titration to <1.8 mmol/L or <70 mg/dL is reasonable.
Choose: Atorvastatin 80 mg/day OD. If triglycerides are ≥5.6 mmol/L or 500 mg/dL, Fenofibrate 150 or 300 mg OD should be started to prevent pancreatitis before LDLlowering therapy is recommended.
III. Coronary Revascularization
In high-risk patients, a routine invasive strategy is generally preferred if there are no contraindications to coronary angiography. Among intermediate-risk patients, the benefits of an invasive approach are attenuated but still present; among low-risk patients, no benefit exists for the routine invasive approach.
A. Urgent coronary angiography/PCI: (<2 h) 
Conclusion
Cardiovascular diseases are currently the leading cause of death in Oman, compared to western patients, our patients have a higher prevalence of cardiovascular risk factors mainly diabetes, hypertension and overweight. Although our in-hospital mortality rates are similar to the western registries, this may be misleading since our patients are about a decade younger than patients in the Western registries. We hope that these clinical pathways will help cardiac caregivers in the front lines to improve outcomes of our NSTE ACS patients.
